Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

A novel mechanism for the protection of embryonic stem cell derived tenocytes from inflammatory cytokine interleukin 1 beta.

McClellan A, Evans R, Sze C, Kan S, Paterson Y, Guest D.

Sci Rep. 2019 Feb 26;9(1):2755. doi: 10.1038/s41598-019-39370-4.

2.

A toolbox for discrete modelling of cell signalling dynamics.

Paterson YZ, Shorthouse D, Pleijzier MW, Piterman N, Bendtsen C, Hall BA, Fisher J.

Integr Biol (Camb). 2018 Jun 18;10(6):370-382. doi: 10.1039/c8ib00026c.

PMID:
29855020
3.

Osteoblast differentiation of equine induced pluripotent stem cells.

Baird A, Lindsay T, Everett A, Iyemere V, Paterson YZ, McClellan A, Henson FMD, Guest DJ.

Biol Open. 2018 May 10;7(5). pii: bio033514. doi: 10.1242/bio.033514.

4.

Characterization of companion animal pluripotent stem cells.

Paterson YZ, Kafarnik C, Guest DJ.

Cytometry A. 2018 Jan;93(1):137-148. doi: 10.1002/cyto.a.23163. Epub 2017 Jul 5. Review.

5.

The Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1.

Markiewski MM, Vadrevu SK, Sharma SK, Chintala NK, Ghouse S, Cho JH, Fairlie DP, Paterson Y, Astrinidis A, Karbowniczek M.

J Immunol. 2017 Apr 1;198(7):2989-2999. doi: 10.4049/jimmunol.1602057. Epub 2017 Feb 22.

6.

Evaluation of the safety and adjuvant effect of a detoxified listeriolysin O mutant on the humoral response to dengue virus antigens.

Hernández-Flores KG, Calderón-Garcidueñas AL, Mellado-Sánchez G, Ruiz-Ramos R, Sánchez-Vargas LA, Thomas-Dupont P, Izaguirre-Hernández IY, Téllez-Sosa J, Martínez-Barnetche J, Wood L, Paterson Y, Cedillo-Barrón L, López-Franco O, Vivanco-Cid H.

Clin Exp Immunol. 2017 Apr;188(1):109-126. doi: 10.1111/cei.12906. Epub 2017 Jan 19.

7.

A One Health overview, facilitating advances in comparative medicine and translational research.

Stroud C, Dmitriev I, Kashentseva E, Bryan JN, Curiel DT, Rindt H, Reinero C, Henry CJ, Bergman PJ, Mason NJ, Gnanandarajah JS, Engiles JB, Gray F, Laughlin D, Gaurnier-Hausser A, Wallecha A, Huebner M, Paterson Y, O'Connor D, Treml LS, Stannard JP, Cook JL, Jacobs M, Wyckoff GJ, Likins L, Sabbagh U, Skaff A, Guloy AS, Hays HD, LeBlanc AK, Coates JR, Katz ML, Lyons LA, Johnson GC, Johnson GS, O'Brien DP, Duan D, Calvet JP, Gandolfi B, Baron DA, Weiss ML, Webster DA, Karanu FN, Robb EJ, Harman RJ.

Clin Transl Med. 2016 Aug;5(Suppl 1):26. doi: 10.1186/s40169-016-0107-4.

8.

Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma.

Mason NJ, Gnanandarajah JS, Engiles JB, Gray F, Laughlin D, Gaurnier-Hausser A, Wallecha A, Huebner M, Paterson Y.

Clin Cancer Res. 2016 Sep 1;22(17):4380-90. doi: 10.1158/1078-0432.CCR-16-0088. Epub 2016 Mar 18.

9.

Schistosoma mansoni soluble egg antigens enhance T cell responses to a newly identified HIV-1 Gag H-2b epitope.

Bui CT, Shollenberger LM, Paterson Y, Harn DA.

Clin Vaccine Immunol. 2015 Feb;22(2):193-9. doi: 10.1128/CVI.00514-14. Epub 2014 Dec 17.

10.

Equine mesenchymal stromal cells and embryo-derived stem cells are immune privileged in vitro.

Paterson YZ, Rash N, Garvican ER, Paillot R, Guest DJ.

Stem Cell Res Ther. 2014 Jul 30;5(4):90. doi: 10.1186/scrt479.

11.

Schistosoma mansoni soluble egg antigens enhance Listeria monocytogenes vector HIV-1 vaccine induction of cytotoxic T cells.

Bui CT, Shollenberger LM, Paterson Y, Harn DA.

Clin Vaccine Immunol. 2014 Sep;21(9):1232-9. doi: 10.1128/CVI.00138-14. Epub 2014 Jul 2.

12.

Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.

Wood LM, Paterson Y.

Front Cell Infect Microbiol. 2014 May 12;4:51. doi: 10.3389/fcimb.2014.00051. eCollection 2014. Review.

13.

HIV-1 vaccine-specific responses induced by Listeria vector vaccines are maintained in mice subsequently infected with a model helminth parasite, Schistosoma mansoni.

Shollenberger LM, Bui CT, Paterson Y, Nyhoff L, Harn DA.

Vaccine. 2013 Nov 19;31(48):5651-8. doi: 10.1016/j.vaccine.2013.09.067. Epub 2013 Oct 8.

PMID:
24120546
14.

Interferon γ-induced intratumoral expression of CXCL9 alters the local distribution of T cells following immunotherapy with Listeria monocytogenes.

Guirnalda P, Wood L, Goenka R, Crespo J, Paterson Y.

Oncoimmunology. 2013 Aug 1;2(8):e25752. Epub 2013 Jul 23.

15.

Live-attenuated Listeria-based immunotherapy.

Rothman J, Paterson Y.

Expert Rev Vaccines. 2013 May;12(5):493-504. doi: 10.1586/erv.13.34. Review.

PMID:
23659298
16.

Successful vaccination of immune suppressed recipients using Listeria vector HIV-1 vaccines in helminth infected mice.

Shollenberger LM, Bui C, Paterson Y, Allen K, Harn D.

Vaccine. 2013 Apr 12;31(16):2050-6. doi: 10.1016/j.vaccine.2013.02.037. Epub 2013 Mar 5.

PMID:
23470236
18.

Listeria monocytogenes-derived listeriolysin O has pathogen-associated molecular pattern-like properties independent of its hemolytic ability.

Wallecha A, Wood L, Pan ZK, Maciag PC, Shahabi V, Paterson Y.

Clin Vaccine Immunol. 2013 Jan;20(1):77-84. doi: 10.1128/CVI.00488-12. Epub 2012 Nov 7.

19.

Listeria monocytogenes and its products as agents for cancer immunotherapy.

Guirnalda P, Wood L, Paterson Y.

Adv Immunol. 2012;113:81-118. doi: 10.1016/B978-0-12-394590-7.00004-X. Review.

PMID:
22244580
20.

The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy.

Wood LM, Pan ZK, Seavey MM, Muthukumaran G, Paterson Y.

Cancer Immunol Immunother. 2012 May;61(5):689-700. doi: 10.1007/s00262-011-1129-9. Epub 2011 Nov 6.

21.

Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice.

Lasaro MO, Sazanovich M, Giles-Davis W, Mrass P, Bunte RM, Sewell DA, Hussain SF, Fu YX, Weninger W, Paterson Y, Ertl HC.

Mol Ther. 2011 Sep;19(9):1727-36. doi: 10.1038/mt.2011.88. Epub 2011 May 17.

22.

Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105.

Wood LM, Pan ZK, Guirnalda P, Tsai P, Seavey M, Paterson Y.

Cancer Immunol Immunother. 2011 Jul;60(7):931-42. doi: 10.1007/s00262-011-1002-x. Epub 2011 Mar 23.

23.

Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy.

Paterson Y, Guirnalda PD, Wood LM.

Semin Immunol. 2010 Jun;22(3):183-9. doi: 10.1016/j.smim.2010.02.002. Epub 2010 Mar 17. Review.

24.

Listeria-derived ActA is an effective adjuvant for primary and metastatic tumor immunotherapy.

Wood LM, Pan ZK, Shahabi V, Paterson Y.

Cancer Immunol Immunother. 2010 Jul;59(7):1049-1058. doi: 10.1007/s00262-010-0830-4. Epub 2010 Mar 6.

25.

Harnessing Listeria monocytogenes to target tumors.

Gravekamp C, Paterson Y.

Cancer Biol Ther. 2010 Feb;9(4):257-65. doi: 10.4161/cbt.9.4.11216. Epub 2010 Feb 1. Review.

26.

High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action.

Kim SH, Castro F, Paterson Y, Gravekamp C.

Cancer Res. 2009 Jul 15;69(14):5860-6. doi: 10.1158/0008-5472.CAN-08-4855. Epub 2009 Jul 7.

27.

Production of polyclonal antisera.

Cooper HM, Paterson Y.

Curr Protoc Neurosci. 2009 Jul;Chapter 5:Unit 5.5. doi: 10.1002/0471142301.ns0505s48.

PMID:
19575471
28.

Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization.

Mustafa W, Maciag PC, Pan ZK, Weaver JR, Xiao Y, Isaacs SN, Paterson Y.

Viral Immunol. 2009 Jun;22(3):195-204. doi: 10.1089/vim.2008.0071.

30.

Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics.

Wallecha A, Carroll KD, Maciag PC, Rivera S, Shahabi V, Paterson Y.

Adv Appl Microbiol. 2009;66:1-27. doi: 10.1016/S0065-2164(08)00801-0. Review.

PMID:
19203646
31.

A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.

Seavey MM, Pan ZK, Maciag PC, Wallecha A, Rivera S, Paterson Y, Shahabi V.

Clin Cancer Res. 2009 Feb 1;15(3):924-32. doi: 10.1158/1078-0432.CCR-08-2283.

32.

Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting.

Seavey MM, Paterson Y.

Breast Cancer (Dove Med Press). 2009 Oct 5;1:19-30. eCollection 2009.

33.

Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy.

Wallecha A, Maciag PC, Rivera S, Paterson Y, Shahabi V.

Clin Vaccine Immunol. 2009 Jan;16(1):96-103. doi: 10.1128/CVI.00274-08. Epub 2008 Nov 19.

34.

Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors.

Wood LM, Guirnalda PD, Seavey MM, Paterson Y.

Immunol Res. 2008;42(1-3):233-45. doi: 10.1007/s12026-008-8087-0.

35.
36.

Production of polyclonal antisera.

Cooper HM, Paterson Y.

Curr Protoc Cytom. 2008 Jan;Appendix 3:Appendix 3I. doi: 10.1002/0471142956.cya03is43.

PMID:
18770642
37.

Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases.

Kim SH, Castro F, Gonzalez D, Maciag PC, Paterson Y, Gravekamp C.

Br J Cancer. 2008 Sep 2;99(5):741-9. doi: 10.1038/sj.bjc.6604526. Epub 2008 Aug 19.

38.

Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors.

Sewell DA, Pan ZK, Paterson Y.

Vaccine. 2008 Sep 26;26(41):5315-20. doi: 10.1016/j.vaccine.2008.07.036. Epub 2008 Aug 3.

39.

Production of polyclonal antisera.

Cooper HM, Paterson Y.

Curr Protoc Immunol. 2001 May;Chapter 2:Unit 2.4. doi: 10.1002/0471142735.im0204s13. Review.

PMID:
18432769
40.

Production of polyclonal antisera.

Cooper HM, Paterson Y.

Curr Protoc Neurosci. 2001 May;Chapter 5:Unit 5.5. doi: 10.1002/0471142301.ns0505s00.

PMID:
18428504
41.

Development of a Listeria monocytogenes based vaccine against prostate cancer.

Shahabi V, Reyes-Reyes M, Wallecha A, Rivera S, Paterson Y, Maciag P.

Cancer Immunol Immunother. 2008 Sep;57(9):1301-13. doi: 10.1007/s00262-008-0463-z. Epub 2008 Feb 14.

PMID:
18273616
42.

Determination of the specific antibody titer.

Cooper HM, Paterson Y.

Curr Protoc Mol Biol. 2001 May;Chapter 11:Unit11.17. doi: 10.1002/0471142727.mb1117s50.

PMID:
18265072
43.

Purification of immunoglobulin G fraction from antiserum, ascites fluid, or hybridoma supernatant.

Cooper HM, Paterson Y.

Curr Protoc Mol Biol. 2001 May;Chapter 11:Unit11.14. doi: 10.1002/0471142727.mb1114s50.

PMID:
18265071
44.

Production of polyclonal antisera.

Cooper HM, Paterson Y.

Curr Protoc Mol Biol. 2008 Jan;Chapter 11:Unit 11.12. doi: 10.1002/0471142727.mb1112s81.

PMID:
18231979
45.

Production of polyclonal antisera.

Cooper HM, Paterson Y.

Curr Protoc Cell Biol. 2001 May;Chapter 16:Unit 16.2. doi: 10.1002/0471143030.cb1602s03.

PMID:
18228334
46.

Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.

Neeson P, Pan ZK, Paterson Y.

Cancer Immunol Immunother. 2008 Apr;57(4):493-505. Epub 2007 Sep 18.

PMID:
17876582
47.

Immunoediting sculpts tumor epitopes during immunotherapy.

Singh R, Paterson Y.

Cancer Res. 2007 Mar 1;67(5):1887-92.

48.
49.
50.

Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy.

Peng X, Treml J, Paterson Y.

Cancer Immunol Immunother. 2007 Jun;56(6):797-806. Epub 2006 Nov 11.

Supplemental Content

Loading ...
Support Center